Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Background : The incidence of thiopurine‐induced hepatotoxicity in patients with inflammatory bowel disease varies in different studies. Aims : To assess the rate of thiopurine‐induced liver toxicity in patients with inflammatory bowel disease; to determine the predictive factors and to characterize its clinical course and management. Methods : A cohort of 161 patients was prospectively followed for a median of 271 days. Hepatotoxicity was established when alanine transaminase or alkaline phosphatase plasma levels were greater than twice the upper normal limit. Results : Abnormal liver function was detected in 21 patients (13%; 95% CI: 7–18). Hepatotoxicity occurred in 16 patients (10%; 95% CI: 6–16) after a median of 85 days. In five cases, treatment was withdrawn due to hepatotoxicity. Use of corticosteroids was associated with hepatotoxicity (OR: 4.94; 95% CI: 1.01–23.98) with antitumour necrosis factor concomitant therapy showing a protective role (OR: 0.3; 95% CI: 0.1–3.1). γ‐Glutamyl transferase plasma levels at the onset of hepatotoxicity showed the best predictive value for treatment withdrawal (area under the receiver operating characteristic curve: 0.95). Conclusions : The incidence of hepatotoxicity in inflammatory bowel disease patients receiving thiopurines is relevant, mainly in patients co‐treated with corticosteroids. γ‐Glutamyl transferase plasma level is a useful biomarker in therapy withdrawal prediction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Cited by
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Chaparro, M., Ordás, I., Cabré, E., Garcia-Sanchez, V., Bastida, G., Peñalva, M., Gomollón, F., García-Planella, E., Merino, O., Gutiérrez, A., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f28f · Cited by 297
Self-citationReview article: drug hepatotoxicity
CHANG, C. Y., & SCHIANO, T. D. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03307.x · Cited by 264
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease
Boonstra, K., van Erpecum, K. J., van Nieuwkerk, K. M. J., Drenth, J. P. H., Poen, A. C., Witteman, B. J. M., Tuynman, H. A. R. E., Beuers, U., & Ponsioen, C. Y. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22938 · Cited by 262
Risk of liver disease in methotrexate treated patients
Conway, R., & Carey, J. J. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i26.1092 · Cited by 170
Metadata
- Authors
- BASTIDA, G., NOS, P., AGUAS, M., BELTRÁN, B., RUBÍN, Á., DASÍ, F., & PONCE, J.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-10-14
- Volume
- 22
- Issue
- 9
- Pages
- 775-782
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1970611979
- Cited by
- 121
- References
- 2
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.2005.02636.x
- The paper
- BASTIDA, G., NOS, P., AGUAS, M., BELTRÁN, B., RUBÍN, Á., DASÍ, F., & PONCE, J. (2005). Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2005.02636.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.